Case of vemurafenib‐induced Sweet's syndrome

Yorio, Jeffrey T.; Mays, Steven R.; Ciurea, Ana M.; Cohen, Philip R.; Wang, Wei‐Lien; Hwu, Wen‐Jen; Gonzalez, Nydia; Richard, Jessica L.; Kim, Kevin B.

doi:10.1111/1346-8138.12430

Cited by 38 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As new drugs are used, isolated case reports of drug‐induced Sweet syndrome continuously appear in the literature. Dermatologists should know that cases of Sweet syndrome have been attributed to isotretinoin, adalimumab, vemurafenib and ipilimumab, as well as bortezomib, azathioprine and antibiotics, among other drugs.…”

Section: Sweet Syndromementioning

confidence: 99%

Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses

Wallach¹,

Vignon‐Pennamen

2015

Br J Dermatol

View full text Add to dashboard Cite

Pyoderma gangrenosum, a dramatic ulcerative skin disease, and Sweet syndrome, a papular dermatosis, were described independently. It was subsequently shown that they share many characteristics, including clinical overlap and the frequent association with multisystemic disorders. The group of the neutrophilic dermatoses encompasses these two dermatoses, as well as other conditions having in common an aseptic neutrophilic infiltrate predominating in the epidermis and/or the dermis and/or the subcutis. Some patients also experience neutrophilic infiltrates in other organs, defining the neutrophilic disease. Recent research suggests that the neutrophilic dermatoses could be considered as the cutaneous expression of the autoinflammation, an aberrant hyperproduction of interleukin-1. Autoinflammation is responsible for monogenic diseases, and is also involved in the mechanism of many polygenic conditions, including the neutrophilic dermatoses.

show abstract

Section: Sweet Syndromementioning

confidence: 99%

Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses

Wallach¹,

Vignon‐Pennamen

2015

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…These conditions include acute febrile neutrophilic dermatosis (Sweet’s syndrome), pustular vasculitis, neutrophilic dermatosis of the dorsal hand, pyoderma gangrenosum, and neutrophilic panniculitis. Sweet’s syndrome 78,79 , mainly a dermal process, and neutrophilic panniculitis, mainly a subcutaneous process, have been attributed to the use of BRAF inhibitors 78–84 .…”

Section: Adverse Effects Of Braf Inhibitors and Suggested Managementmentioning

confidence: 99%

BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

et al. 2014

View full text Add to dashboard Cite

The U.S. Food and Drug Administration–approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine–refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30–40%. In this review, we discuss BRAF inhibitors in the context of thyroid cancer, the toxicities associated with BRAF inhibitors, and the suggested management of those toxicities. The management of vemurafenib and dabrafenib toxicities is applicable across all tumor types and may serve as a practical guide to their use.

show abstract

“…One uncommon but very interesting side effect already mentioned above is the onset of neutrophilic dermatoses during the administration of BRAF inhibitors. There have been reports of lobular panniculitis, Sweet's syndrome, and neutrophilic eccrine hidradenitis [67][68][69].…”

Section: Cutaneous Lesions Caused By Braf and Mek Inhibitorsmentioning

confidence: 99%

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

et al. 2018

View full text Add to dashboard Cite

Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management.

show abstract

Case of vemurafenib‐induced Sweet's syndrome

Cited by 38 publications

References 15 publications

Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses

Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses

BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

Contact Info

Product

Resources

About